GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (HKSE:02269) » Definitions » Price-to-Funds-From-Operations

WuXi Biologics (Cayman) (HKSE:02269) Price-to-Funds-From-Operations : (As of May. 24, 2024)


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


WuXi Biologics (Cayman) (HKSE:02269) Business Description

Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.
Executives
Blackrock, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Li Ge 2201 Interest of corporation controlled by you
Citigroup Inc. 2502 Approved lending agent
Brown Brothers Harriman & Co. 2502 Approved lending agent
Zhao Ning 2202 Interest of your spouse
Liu Xiaozhong 2401 A concert party to an agreement to buy shares
New Wuxi Life Science Holdings Limited 2201 Interest of corporation controlled by you
New Wuxi Life Science Limited 2201 Interest of corporation controlled by you
Wuxi Biologics Holdings Limited 2101 Beneficial owner
Wuxi Pharmatech (cayman) Inc. 2201 Interest of corporation controlled by you
Zhang Zhaohui 2401 A concert party to an agreement to buy shares
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you